Literature DB >> 1372666

[Application of FDA/EB staining for the detection of viable or non-viable mycobacteria in clinical specimens].

S Harada1, N Numata.   

Abstract

Two-hundred sputum specimens from tuberculosis patients were examined for viable or non-viable mycobacteria by a combination of fluorescein diacetate ethidium bromide (FDA/EB) staining, Ziehl-Neelsen staining, and the use of cultures in 3% Ogawa egg medium. The sputum specimens were treated with 3% NaOH for 10 min and washed in PBS. The bacteria was then harvested by centrifugation at 6,000 rpm for 5 min. Each sample was subjected to FDA/EB staining, Ziehl-Neelsen staining and cultures to compare the staining -method results and the results of colony formation. Ziehl-Neelsen staining method revealed acid-fast bacteria in the specimens, distributed from Gaffky 1 to Gaffky 8. The number of FDA-positive specimens and culture-positive specimens were identical in all Gaffky grades, suggesting that the FDA staining method well reflected the presence of viable mycobacteria in the specimens. We concluded that FDA staining is a valuable method to detect viable mycobacteria in sputum specimens on the first day of examination. It is therefore advantageous for doctors and patients to be immediately informed of culture results rather than waiting for several weeks.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1372666

Source DB:  PubMed          Journal:  Kekkaku        ISSN: 0022-9776


  8 in total

1.  Field evaluation of a simple fluorescence method for detection of viable Mycobacterium tuberculosis in sputum specimens during treatment follow-up.

Authors:  Birgit Schramm; Cathy Hewison; Laurence Bonte; Warren Jones; Olivier Camélique; Ronnatrai Ruangweerayut; Witaya Swaddiwudhipong; Maryline Bonnet
Journal:  J Clin Microbiol       Date:  2012-05-30       Impact factor: 5.948

2.  Pulmonary Tuberculosis Conversion Documented by Microscopic Staining for Detection of Dynamic, Dormant, and Dead Mycobacteria (DDD Staining).

Authors:  A Loukil; F Darriet-Giudicelli; C Eldin; M Drancourt
Journal:  J Clin Microbiol       Date:  2018-09-25       Impact factor: 5.948

Review 3.  Tuberculosis in the developing world: recent advances in diagnosis with special consideration of extensively drug-resistant tuberculosis.

Authors:  Louis Grandjean; David A J Moore
Journal:  Curr Opin Infect Dis       Date:  2008-10       Impact factor: 4.915

4.  Editorial commentary: dead or alive: can viability staining predict response to tuberculosis treatment?

Authors:  Stephen D Lawn; Mark P Nicol
Journal:  Clin Infect Dis       Date:  2014-12-23       Impact factor: 9.079

5.  Clinical evaluation of tuberculosis viability microscopy for assessing treatment response.

Authors:  Sumona Datta; Jonathan M Sherman; Marjory A Bravard; Teresa Valencia; Robert H Gilman; Carlton A Evans
Journal:  Clin Infect Dis       Date:  2014-12-23       Impact factor: 9.079

6.  The Assessment of Viability of M. Tuberculosis after Exposure to CPC Using Different Methods.

Authors:  Gomathi Sekar; R Lakshmi; N Selvakumar
Journal:  Int J Bacteriol       Date:  2014-01-28

7.  Optimising fluorescein diacetate sputum smear microscopy for assessing patients with pulmonary tuberculosis.

Authors:  Sumona Datta; Keren Alvarado; Robert H Gilman; Teresa Valencia; Christian Aparicio; Eric S Ramos; Rosario Montoya; Carlton A Evans
Journal:  PLoS One       Date:  2019-04-30       Impact factor: 3.240

8.  Sputum Microscopy With Fluorescein Diacetate Predicts Tuberculosis Infectiousness.

Authors:  Sumona Datta; Jonathan M Sherman; Marco A Tovar; Marjory A Bravard; Teresa Valencia; Rosario Montoya; Willi Quino; Nikki D'Arcy; Eric S Ramos; Robert H Gilman; Carlton A Evans
Journal:  J Infect Dis       Date:  2017-09-01       Impact factor: 5.226

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.